New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
Case Studies & Whitepapers
Development of a personalized digital biomarker of vaccine-associated reactogenicity using wearable sensors and digital twin technology
April 21, 2025
More infoPosters
Qualification of Gene and Protein Signatures from CITE-seq Data for Deep Immunophenotyping in Human Clinical Trials
April 7, 2025
More infoPosters
Beyond Affinity: Simplifying ADC quantitation without compromising sensitivity.
April 7, 2025
More info